FGF21 and metabolic dysfunction-associated steatohepatitis: This finding highlighted the potential pharmacological application of FGF21, especially for its anti-inflammatory effect, as a promising therapeutic strategy for clinical application to treat NASH at an early stage and thereby prevent NASH-HCC transition.